InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (11 ops.)
Insider track record
Board DirectorDisclosed buys
7
Disclosed sells
11
T+90 hit rate
100%
T+90 mean return
+46.7%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Thompson Peter A., Director. Insider active across 7 companies, notably Janux Therapeutics, Inc.. Cumulatively, 23 disclosures have been published. Split: 7 buys · 11 sells. Total volume traded: €66.8m. History available since 17 September 2021. The latest transaction was disclosed on 3 April 2025 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations23 total
372,578 shares@ US$20.1339.2% of flowCommon StockSEC:0000947871-25-000360:0
Ideal exit: 29 Dec 2025 (T+270)
3,154,959 sharesCommon StockSEC:0000950170-25-017031:0
83,695 shares@ US$13.0011.3% of flowCommon StockSEC:0000947871-24-000729:0
394,400 shares@ US$13.5255.5% of flowCommon StockSEC:0000947871-24-000721:0
2,416,181 sharesCommon StockSEC:0001626199-24-000096:0
454,545 shares@ US$11.0026.5% of flowCommon StockSEC:0000947871-24-000070:0
Ideal exit: 19 Oct 2024 (T+270)
145,251 shares@ US$12.7436.5% of flowCommon StockSEC:0000947871-24-000033:0
162,576 shares@ US$19.9663.5% of flowCommon StockSEC:0000947871-23-001190:0
500,000 shares@ US$6.2033.1% of flowCommon StockSEC:0000947871-23-000914:0
Ideal exit: 25 May 2024 (T+270)
484,496 shares@ US$10.3228.9% of flowCommon StockSEC:0000947871-22-000973:0
Ideal exit: 13 Jun 2023 (T+270)
138,000 shares@ US$7.210.036% mcap100.0% of flowCommon StockSEC:0000947871-22-000628:0
Ideal exit: 12 Feb 2023 (T+270)
36,700 shares@ US$20.303.9% of flowCommon StockSEC:0000947871-21-001322
36,700 shares@ US$20.300.078% mcap3.9% of flowCommon StockSEC:0000947871-21-001322:0
108,300 shares@ US$19.000.22% mcap10.7% of flowCommon StockSEC:0000947871-21-001314:0
108,300 shares@ US$19.0010.7% of flowCommon StockSEC:0000947871-21-001314
356,800 shares@ US$19.0735.4% of flowCommon StockSEC:0000947871-21-001300
356,800 shares@ US$19.070.71% mcap35.4% of flowCommon StockSEC:0000947871-21-001300:0
1,109,644 shares@ US$6.090.56% mcap50.0% of flowCommon Stock, $0.0001 par valueSEC:0000947871-21-001016:0
1,109,644 shares@ US$6.0950.0% of flowCommon Stock, $0.0001 par valueSEC:0000947871-21-001016
585,106 shares@ US$9.4050.0% of flowCommon StockSEC:0000947871-21-001009:0
Ideal exit: 14 Jun 2022 (T+270)
585,106 shares@ US$9.4050.0% of flowCommon StockSEC:0000947871-21-001009
Ideal exit: 14 Jun 2022 (T+270)
1,348,421 sharesCommon StockSEC:0001209191-21-041058:0
1,348,421 sharesCommon StockSEC:0001209191-21-041058
23 of 23 declarations
About Thompson Peter A.
Peter A. Thompson is a Board Member at Janux Therapeutics, Inc., Alpine Immune Sciences, Inc., and Corvus Pharmaceuticals, Inc. He plays a key role in the governance of these companies, bringing his expertise in strategy and business development. Thompson is involved in overseeing performance and growth initiatives, thereby contributing to the achievement of organizational goals.
